Bedrijfsoverzicht
Elicio Therapeutics, Inc. is a clinical-stage biotechnology entity focused on the development of immunotherapies designed to treat cancer. The company operates within the healthcare sector and specifically functions in the biotechnology industry, which is characterized by high research and development expenditures and a reliance on successful clinical trial outcomes for commercialization. Elicio Therapeutics, Inc. currently has a market capitalization of $186.72M and employs a workforce of 33 individuals. The market cap figure of $186.72M, combined with the lack of reported annual revenue data (N/A), indicates that the company is in a pre-revenue or early commercialization stage where valuation is primarily driven by asset potential rather than current cash flows. This small employee count of 33 suggests a lean operational structure typical of clinical-stage firms that prioritize capital allocation toward research and development rather than extensive administrative overhead. The absence of significant revenue generation further contextualizes the company's position as a venture-stage entity seeking to bridge the gap between laboratory innovation and market entry.
Financiële gezondheid
The company reports a net income of $-39,571,000 and an EBITDA of $-37,510,000, while revenue data is not available (N/A). The substantial gap between revenue (which is effectively zero or unreported) and the significant net loss reveals a cost structure dominated by research, development, and clinical trial expenses rather than cost of goods sold. Free cash flow stands at $-21,666,376, indicating that the company is consuming cash to fuel its operations and development pipeline, which limits current financial flexibility but is standard for clinical-stage biotechs. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is consistent with a company that has not yet generated commercial revenue or is operating in a phase where costs vastly exceed income. The company holds $18.56M in cash against $14.51M in debt, resulting in a debt-to-equity ratio of 887.04. This high debt-to-equity ratio, coupled with the cash position, suggests a balance sheet that is currently leveraged but supported by liquid assets, though the high ratio reflects the lack of equity value relative to liabilities in a pre-profitability model. The current ratio is 2.38, indicating that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for immediate operational needs. Return on Equity is N/A due to the lack of positive equity earnings, while Return on Assets is -87.2%, which reflects the heavy asset utilization required for R&D without corresponding profitability. These return metrics reveal that management effectiveness is currently measured by the ability to preserve cash and advance clinical programs rather than generating shareholder returns through profit.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A because the company has not generated positive earnings, while the forward P/E is listed as -7.25. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing the stock based on future earnings expectations that are currently negative or undefined. The price-to-book ratio is 110.33, which indicates a significant market premium over the company's book value, reflecting the high value placed on the company's intellectual property and clinical pipeline assets. The price-to-sales ratio is N/A and the EV/EBITDA is -4.87, suggesting that traditional sales-based valuation methods are not applicable yet, and the negative EV/EBITDA highlights the cash-burn nature of the business relative to its enterprise value. The 52-week high is $14.93 and the 52-week low is $4.61; without a specific current price provided in the source text, the valuation range is defined strictly by these historical bounds which demonstrate significant volatility over the past year. The beta value is 1.88, indicating that the stock price is expected to be 88% more volatile than the broader market, a characteristic common in small-cap biotechnology stocks. This high beta suggests that the stock price will likely experience larger swings in response to market movements or specific industry news compared to large-cap equities.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is also N/A, as the company has not yet achieved consistent commercial profitability. Because the company is in a clinical-stage development phase, it is not possible to determine whether earnings are growing faster or slower than revenue, as both metrics are currently undefined or negative. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the company does not distribute earnings to shareholders, any available cash or potential future profits are necessarily reinvested into growth initiatives such as advancing clinical trials for ELI-002. The overall growth and income profile for Elicio Therapeutics, Inc. is characterized by a complete reliance on external capital sources and internal cash reserves to fund operations, with no current income generation or dividend distribution to investors.